This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2001;286:527.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved drospirenone, 3.0 mg, and ethinyl estradiol, 0.030 mg (Yasmin 28 tablets; Berlex Laboratories, Wayne, NJ), an oral contraceptive, for prevention of pregnancy. The drug was approved on the basis of results of clinical studies of up to 2 years' duration, in which 2629 women completed 33 160 cycles of Yasmin use without any other contraception. Their mean (SD) age was 25.5 (4.7) years, and the pregnancy rates in these studies were less than 1 per 100 person-years of use.

Yasmin is the first oral contraceptive approved by the FDA that contains the progestin drospirenone, an analog of spironolactone. The 3-mg dose of drospirenone has antimineralocorticoid activity, including a risk of hyperkalemia, comparable to a 25-mg dose of spironolactone. Yasmin should not be used by patients with conditions that predispose them to high potassium concentrations in blood, ie, renal insufficiency, hepatic dysfunction, and adrenal insufficiency. Women receiving daily, . . . [Full Text of this Article]